Performance Based Pricing
From Patient Determinants
- Novartis, CMS collaborate on outcomes-based pricing for $475k leukemia drug (8/31/17)
- A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)
- Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)
- Cigna, Novartis agree on outcome-based price for heart drug (2/9/16)
- Cigna first insurer to reach value-based agreements for new class of cholesterol drugs (5/12/16)
See Health Insurance Payment Models - Performance Based Pricing
